Market News & Trends
LSP & Bristol-Myers Squibb Enter Strategic Collaboration for Life Sciences Innovation
LSP (Life Sciences Partners) recently announced a strategic collaboration with Bristol-Myers Squibb Company in which the companies will work closely together in identifying European breakthrough…
Novozymes Half-Life Extension Technology Embraced by Paras Biopharmaceuticals to Develop New Biobetter
Novozymes Biopharma and Paras Biopharmaceuticals will collaborate to generate an improved version (a biobetter) of Teriparatide, a leading treatment for osteoporosis, a debilitating bone disease…
Summit Therapeutics Announces Novel Antibiotic Ridinilazole Achieves Statistical Superiority Over Vancomycin
Summit Therapeutics plc recently announced the success of CoDIFy, a Phase II proof- of-concept clinical trial that evaluated the novel, oral antibiotic, ridinilazole (SMT19969) against…
Global Type 1 Diabetes Mellitus Market Value Will Exceed $7 Billion
The Type 1 Diabetes Mellitus (T1DM) market across the eight major countries of the US, Canada, France, Germany, Italy, Spain, the UK, and Japan will…
UPM Pharmaceuticals Seeking to Fill 8 Positions
Qualified candidates please reference job title and email resume and salary requirements to:humanresources@upm-inc.com UPM Pharmaceuticals, Inc. (www.upm-inc.com), a growing contract drug development and manufacturing…
Concert Pharmaceuticals Achieves $2-Million Milestone From Avanir Pharmaceuticals
Concert Pharmaceuticals, Inc. recently announced it has achieved a $2-million milestone under its development and license agreement with Avanir Pharmaceuticals, Inc. for the progression of…
GENFIT Announces Pivotal Phase III Clinical Trial
GENFIT recently announced the design of the global Phase III trial to evaluate the benefits of Elafibranor treatment on NASH patients. The pivotal trial will…
Baxter Completes Capacity Expansion to Support Oncology Contract Manufacturing Services
Baxter International Inc.’s BioPharma Solutions business, a premier contract manufacturing organization (CMO) that specializes in parenteral pharmaceuticals, recently announced it has completed an approximately 1,800-square-meter…
Xenetic Biosciences Enters Into Asset Purchase Agreement
Xenetic Biosciences, Inc. recently announced it has entered into an Asset Purchase Agreement with AS Kevelt and OJSC Pharmsynthez. Pursuant to the APA, the Sellers…
Adare Pharmaceuticals Partners With Cincinnati Children’s on Innovation Fund
Adare Pharmaceuticals, Inc. and the Cincinnati Children’s Hospital Medical Center recently announced they are partnering together on an Innovation Fund, which will focus on optimizing…
Catalent Biologics Expands Analytical & Process Development Capabilities
Catalent Pharma Solutions recently announced the multi-site expansion of its analytical and process development capabilities for biologics. These investments include a significant expansion of bioassay…
Aptose Biosciences Announces Collaborations for New Multi-Targeting Epigenetic Therapeutic Agents
Aptose Biosciences Inc. recently announced two collaborations that will provide exclusive access to new epigenetic therapeutics for the company's oncology pipeline. These partnerships have been…
Resverlogix Commences Dosing in Phase II Clinical Trial
Resverlogix Corp. recently announced that the first patient has been randomized and dosing has commenced in the Phase III clinical trial BETonMACE with lead drug…
NightstaRx Announces Start of Miami Gene Therapy Study
NightstaRx Ltd recently announced that the Bascom Palmer Eye Institute of the University of Miami Miller School of Medicine, has begun enrolling and dosing subjects…
Juniper Pharma Adds Three New Products to Its Proprietary Pipeline
Juniper Pharmaceuticals, Inc. recently announced details of its portfolio pipeline, focused on three new product candidates to treat women's health conditions, at its Investor Day…
Cancer Genetics Announces Closing Of $12 Million Public Offering
Cancer Genetics, Inc. recently confirmed the closing of its previously announced public offering of 3,000,000 shares of its common stock with 5-year warrants to purchase…
Epic Sciences Partners With University of Pennsylvania's Abramson Cancer Center
Epic Sciences, Inc. recently announced a collaboration with the Abramson Cancer Center of the University of Pennsylvania (Penn) on multiple studies to explore biomarkers, identified…
12th Annual BioProcess International Conference & Exposition Is Largest in Its History
- Global Forum Focused On Advancing Drug Candidates Closer to Approval Faster and More Efficiently Sets Attendance, Exhibitor…
First Patient Dosed in Clinical Trial of Halozyme’s Investigational Drug in Combination With Merck’s Immuno-Oncology Drug
Halozyme Therapeutics, Inc. recently announced the first patient has received its investigational new drug, PEGPH20 in combination with Merck's KEYTRUDA (pembrolizumab) in a clinical trial…
FDA Grants Fast-Track Designation for Development of CAM2038, Long-Acting Buprenorphine Injections to Treat Opioid Addiction
Braeburn Pharmaceuticals and Camurus recently announced that the US FDA granted Fast-Track designation for the CAM2038 weekly and monthly buprenorphine subcutaneous injection products under development…